Abstract Severe aortic stenosis (AS) is a life-threatening condition when left untreated. Aortic valve replacement (AVR) is the gold standard treatment for the majority of patients; however, transcatheter aortic valve implantation/replacement (TAVI/TAVR) has emerged as the preferred treatment for high-risk or inoperable patients. The concept of transcatheter heart valves originated in the 1960s and has evolved into the current Edwards Sapien and Medtronic CoreValve platforms available for clinical use. Complications following TAVI, including cerebrovascular events, perivalvular regurgitation, vascular injury, and heart block have decreased with experience and evolving technology, such that ongoing trials studying TAVI in lower risk patients have become tenable. The multidisciplinary team involving the cardiac surgeon and cardiologist plays an essential role in patient selection, procedural conduct, and perioperative care.
Introduction
Severe aortic stenosis (AS) is a life-threatening condition when left untreated. The most common causes of AS are degenerative disease, bicuspid aortic valve disease, and rheumatic valve disease. The natural history of AS is progressive, manifested by dyspnea, angina, and syncope, with an average life expectancy ) is a class I recommendation for patients with severe, symptomatic AS and has been associated with low operative mortality in high-volume centers [1] . While AVR has traditionally been performed using a median sternotomy, minimally invasive approaches using a right anterior thoracotomy or upper hemisternotomy potentially offer lower perioperative morbidity without compromising safety [2] .
Nevertheless, AVR requires cardiopulmonary bypass mandatory periods of cardiac ischemia during aortic cross-clamping. Moreover, many patients are not referred for AVR due to conditions such as advanced age, frailty, left ventricular dysfunction, or comorbidities that preclude surgery or contribute to high perioperative risks (Fig. 1) . Transcatheter aortic valve replacement (TAVR) or implantation (TAVI) has emerged as an accepted treatment for patients considered inoperable or high risk for AVR. Here, we review the history, devices, complications, and future directions of TAVI.
History of TAVI
Hywel Davies described the first use of a percutaneously implanted cardiac valve in a 1965 study where a parachute-like valve was delivered through the femoral artery in dogs with experimentally created aortic regurgitation (AR) [3] . Further developments included a catheter-mounted inflatable balloon and umbrella-like valves by Spyridon Moulopoulos in 1971 [4] and a similar system by Steven Phillips in 1976 [5] , both of which required permanent attachment to delivering catheters for AR treatment. Henning Anderson developed a transluminal catheter technique to implant an artificial aortic valve in pigs in 1992 using a balloon-expandable stent. Although he demonstrated a successful reduction in transvalvular gradient, coronary flow was compromised in one third of the pigs [6] . Philipp Bonhoeffer performed the first human percutaneous valve implantation in a 12-year-old boy with stenosis and insufficiency of a prosthetic conduit from the right ventricle to the pulmonary artery with a bovine jugular valve in 2000 [7] .
In 2002, Alain Cribier performed the first human TAVI using a balloon-expandable valve through a trans-septal approach in a 57-year-old-male with severe AS, cardiogenic shock, and a left ventricular (LV) ejection fraction of 12 % [8] . The first selfexpanding valve was implanted in a human in 2004 using a bovine pericardial trileaflet nitinol stent in a 73-year-old woman with severe symptomatic AS using a retrograde approach through the common iliac artery [9] . Thus began the era of TAVI as the balloon-expandable valve gave rise to the Sapien valve line by Edwards Lifesciences (Irvine, CA, USA), and the self-expanding valve gave rise to the CoreValve line by Medtronic (Irvine, CA, USA). Commercial TAVI approval occurred in Europe in 2007 followed by the USA in 2011.
Access
Transfemoral, transapical, transaxillary, and transaortic approaches are currently approved for TAVI access. Transcarotid and transcaval approaches have shown feasibility, but limited data are available on their safety and efficacy.
The most common and preferred access is the transfemoral approach which involves retrograde common femoral arterial access. It is the only approach which offers the possibility of a completely percutaneous procedure without any surgical incisions. Initially, half of TAVI cases were performed using the transfemoral approach due to large delivery sheaths (up to 26Fr). By convention, sheaths are listed by their inner diameter, while catheters are listed using their outer diameter. As the technology improved, a smaller sheath (down to 14Fr) increased transfemoral use to nearly 90 % of TAVI cases [10] . Percutaneous closure devices using the Bpreclose techniqueŝ uch as ProGlide (Abbott Vascular, Santa Clara, CA, USA) has enabled closure of the arterial puncture without surgical repair [11] . ProGlide is approved for closure of 5-21Fr femoral arterial punctures, but sheaths larger than 8F require at least two devices. The ProStar (Abbot Vascular, Santa Clara, CA, USA) is also used with the preclose technique in 8.5-10Fr femoral access sites. The transapical approach involves direct puncture of the LV apex via a left mini-thoracotomy, providing a direct route to the aortic valve with no limit to the size of the delivery system, and avoidance of diseased aorta and peripheral vasculature. Drawbacks of this access are apical bleeding, mechanical myocardial injury, mitral structural injury, the need for endotracheal intubation, and incisional pain [12] . Percutaneous closure devices for transapical devices are in development.
The transaortic approach involves direct puncture of the ascending aorta through either a partial sternotomy or right anterior thoracotomy [13] . Similar to transapical access, this approach is not limited by sheath size and maintains a short working distance to the valve. Drawbacks include aortic calcifications precluding safe puncture and incisional pain.
The transaxillary approach is a retrograde arterial approach using the axillary artery through surgical cutdown [14] , although a percutaneous approach has been described [15] . In addition to sheath size limitations, patients with a patent left internal mammary artery conduit require 1.5-2-mm larger diameter for satisfactory perfusion of the myocardium during procedures.
The transcarotid approach is a retrograde arterial approach via the carotid artery. Patients undergoing carotid access may tolerate temporary unilateral carotid occlusion, having adequate anterior communicating artery at the circle of Willis. However, passive antegrade carotid perfusion through a temporary shunt into the common carotid has been described [16] . In a series of 12 patients, the procedure was successfully applied without mortality but one episode of stroke [17] .
The transcaval approach involves femoral venous puncture with subsequent caval-aortic puncture in the abdomen [18] . Careful selection of patients with acceptable proximity of the inferior vena cava and abdominal aorta is required. The cavalaortic tract can typically be closed successfully with nitinol occluder devices, and is, counterintuitively, well tolerated when not repaired [19] . 
TAVI Indications

Platforms Edwards Sapien Valve
The Edwards Sapien platform features a bovine pericardium valve mounted onto a balloon-expandable stent comprised of stainless steel (first generation) or chromium cobalt (Sapien XT and Sapien 3) (Fig. 2, Table 1 ). The first generation valve was approved in 2011, but is no longer commercially available. Valve sizes included 23 and 26 mm, using a transfemoral, transapical, or transaortic approaches with 22-26Fr sheaths. In 2014, the Sapien XT valve was approved for use in inoperable or high-risk patients with AS, featuring a 29-mm-size and smaller sheaths (16, 18, 20Fr ). The Sapien 3 (approved in June 2015) features a 20-mm valve, a sealing cuff to reduce perivalvular regurgication (PVR), and further profile reduction, requiring 14 and 16Fr sheaths. Moreover, through a dynamic expansion mechanism, the SAPIEN3 eSheath system can transiently expand to accommodate larger sheath sizes.
The PARTNER Trial (inoperable cohort) randomized nearly 360 prohibitive-risk patients to either TAVI or medical treatment, which included a balloon aortic valvuloplasty in 79 % of this arm. The primary outcome of all-cause mortality was 30.7 % in the TAVI group and 49.7 % in the standard therapy group (p < 0.001) at 1 year [22] . The reduction in all-cause mortality was maintained at 5 years with 71.8 % mortality in the TAVI group compared to 93.6 % in the standard treatment group (HR 0.50, 95 % CI 0.39-0.65; p < 0.0001). At 5 years, 42 (86 %) of 49 survivors in the TAVI group had New York Heart Association class I or II symptoms compared with three (60 %) of five in the standard treatment group. Moreover, post-TAVI echocardiography showed durable hemodynamic benefit (aortic valve area The PARTNER Trial's high-risk cohort randomized nearly 700 patients to TAVI or SAVR. At 1 year, TAVI was not inferior to SAVR in terms of mortality (24.2 vs 26.8 %, p = 0.44), and this noninferiority was maintained through 5 years (67.8 vs 62.4 %, p = 0.76) [22, [24] [25] [26] [27] . In addition, no structural valve deterioration requiring intervention in either group. Moderate or severe AR occurred in 40 (14 %) of the 280 patients in the TAVI group and two (1 %) of 228 in the SAVR group (p < 0.0001), and was associated with an increased 5-year risk of mortality in the TAVI group (72.4 % for moderate or severe AR vs 56.6 % for mild AR or less; p = 0.003) ( Table 1) 
The PARTNER II Trial led to Sapien XT valve approval and expanded TAVI indications to Bvalve-in-valve^treatment for patients with failed aortic bioprosthesis. Cohort B of the PARTNER II study randomized patients with severe, symptomatic AS, and prohibitive surgical risk to transfemoral TAVI with SAPIEN or SAPIEN XT. At 1 year, patients receiving SAPIEN XT had a similar composite rate of mortality, major stroke, and rehospitalization to patients receiving SAPIEN (37.2 vs 37.7%, noninferiority p value <0.002) [29] .
Medtronic CoreValve
The Medtronic CoreValve consists of a trileaflet porcine pericardial valve mounted supraannularly onto a nitinol self-expanding stent (Fig. 3 , Table 1 ). The aortic annulus and ascending aorta serve as points of fixation. The CoreValve is available in 23-, 26-, 29-and 31-mm sizes and can be delivered through transfemoral, transaortic, or transaxillary approaches. The FDA approved the CoreValve platform for use in inoperable patients in January 2014, followed by approval for high-risk patients in June 2014. In June 2015, the FDA approved the recapturable and repositionable device CoreValve Evolut R, which is presently the only repositionable TAVI device available in the USA.
Prohibitive-risk patients were studied in the CoreValve pivotal trial in a non-randomized fashion due to the positive results of the PARTNER Trial. In this Bextreme high-risk^co-hort, mortality at 1 year was 24.3 %, superior to the prespecified objective performance goal of 43.0 % (p < 0.0001) [30] . The as-treated analysis of the CoreValve high-risk trial showed all-cause mortality at 1 year was lower in the TAVI group than in the AVR group (14.2 % vs. 19.1 %) with an absolute risk reduction of 4.9 % (p < 0.001 for noninferiority; The CoreValve Evolut R is also approved for Bvalve-invalve^treatment for failed aortic bioprosthetic valves. The supraanular design allows CoreValve to achieve an augmented effective outflow orifice than in the original bioprosthetic surgically implanted valve and has lower gradients than the Sapien XT in smaller valve sizes [33] .
Lotus Valve
The Lotus Valve consists of three bovine pericardial leaflets hand-sewn onto the valve frame, which is braided from a single nitinol wire, the ends of which are joined by a radiopaque, tantalum marker (Fig. 4) . The tantalum marker is positioned at the mid-frame height and acts as a fluoroscopic aid for accurate valve positioning. The Lotus prosthesis uses a unique controlled mechanical expansion mechanism as opposed to balloon-expandable or self-expanding devices. Deployment results in shortening of the prosthesis along three evenly spaced mandrels around the frame. This brings the ventricular and aortic portions of the locking mechanism together. As the frame shortens from its constrained form to the final height of 19 mm, it radially expands to a final diameter of 23, 25, or 27 mm. A blended polymer membrane surrounds the lower half of the Lotus device designed to reduce perivalvular regurgitation (PVR). On unsheathing, the valve functions immediately, thus reducing the likelihood of hemodynamic instability. The device is fully repositionable, resheathable, and retrievable even from the fully expanded and locked position. This allows complete assessment of the expanded device by fluoroscopy, angiography, and echocardiography prior to final release. The 23-mm Lotus system is compatible with an 18-Fr proprietary femoral sheath while the 27-mm Lotus system requires a 20Fr proprietary femoral sheath.
The Lotus Valve has a CE Mark in Europe but is only available through clinical trial in the USA. REPRISE II is a prospective, single-arm clinical trial of 120 high-risk patients with severe, symptomatic AS. Early results demonstrated successful repositioning and retrieval in all patients for which it was necessary. At 30 days, the mortality rate was 4.3 %, major stroke rate was 4.2 %, permanent pacemaker implantation rate was 28.6 %, and only one patient had moderate PVR [34] .
Direct Flow Medical Valve
The Direct Flow Medical Valve is a bovine pericardial valve mounted onto a fabric frame (Fig. 5) and is completely repositionable. Positioning is performed with the help of three cables attached to the valve frame, which is available in 23-, 25-, 27-and 29-mm sizes using 18Fr sheaths through a transfemoral access.
The valve is positioned in the left ventricle and partially inflated. At that point, it begins to function and is then carefully pulled upwards to cover the native aortic annulus. After achieving optimal valve positioning, the saline/contrast mix is exchanged under constant pressure for a quick-curing polymer that hardens over several hours. Following initial expansion, the valve remains fully competent throughout the procedure, which allows for safe positioning. The Direct Flow valve has the CE Mark in Europe but is available in the USA only through clinical trial. The Transcatheter Aortic Valve Replacement System Pivotal Trial (SALUS) randomizes high-and prohibitive-risk patients with severe symptomatic AS 2:1 to the Direct Flow valve or CoreValve. The latest iteration of the SALUS trial randomizes high-and prohibitive-risk patients with severe symptomatic AS to the direct flow system to commercially available Medtronic CoreValves [35] .
St. Jude Portico Valve
The Portico is an intra-annular bovine pericardial valve with a porcine pericardial sealing cuff and self-expanding nitinol frame (Fig. 6) . This platform has larger stent cells to improve anatomic conformation and coronary access. A rotating thumbwheel can be used to unsheathe and release the valve, which can then be resheathed, repositioned, or retrieved up to 80 % deployment. The Portico system can be administered through transfemoral, subclavian, transaortic, or transapical approaches.
The Portico trial was briefly stopped due to concerns of valve thrombosis. Reduced aortic valve leaflet motion was present in 16 of 37 (43 %) with Portico valves. The reduced leaflet motion was determined to be related to subclinical valve thrombosis and resolved with therapeutic warfarin anticoagulation but not with dual antiplatelet therapy [36] . The trial resumed once the observation of reduced leaflet mobility was determined to be a class effect which was observed in other TAVI and surgical valves.
Complications
Up to one third of TAVI patients will develop a major complication during the first month after the procedure. Valve Academic Research Consortium (VARC) statements have been the standard in defining complications and their applicability (Table 2) 
Death
Although not a primary end point of the TAVI clinical trials, a 30-day mortality is a key indicator of intervention safety and efficacy. The 30-day all-cause mortality in the PARTNER trial (high-risk cohort) was 3.4 % for TAVI compared to 6.5 % for AVR (p = 0.07) [24] . In the CoreValve pivotal trial, the 30-day mortality was 3.3 % in the TAVI group and 4.5 % in the AVR group (p = 0.43) [31•] . This is consistent with data from a national registry of 3133 patients from 114 hospitals found a 30-day mortality rate of 7.6 %, including 5.0 % for patients at high risk for surgery using the transfemoral approach and 6.7 % for patients who are not operative candidates (prohibitive risk) assigned to the femoral approach [39] .
Cerebrovascular Events
Strokes and transient ischemic attacks (TIAs) are the most feared complications of TAVI. In the first edition of VARC, stroke was defined as a focal or global neurological deficit lasting >24 h resulting from a cerebral, spinal, or retinal dysfunction caused by ischemia or hemorrhage, with neuroimaging evidence of a new lesion. If the neurological episode lasts <24 h and neuroimaging does not demonstrate new hemorrhage or infarct, the event was defined as a TIA [40] . The incidence of cerebrovascular events in the first month is approximately 5 %, with at least 50 % of these events occurring within the first 24 h [41] . This complication is associated with up to a tenfold increase in a 30-day mortality. Some strokes, especially after the first 24 h, are related to atrial fibrillation (AF), as up to one third of all patients undergoing TAVI develop new onset AF [42] . Interestingly, up to 90 % of patients in some studies had clinically silent brain lesions detected on MRI. In one study, in which transcranial Doppler ultrasonography was used during 83 TAVI procedures, high-intensity transient signals indicating microembolization were detected during all interventions, with only two patients experiencing a procedural stroke, and no sequelae among other patients during follow-up. These signals occur mostly during positioning and implantation of the valve. In the histopathology report of the particles caught with filter-like protection devices, thrombotic material was found in 52 % of patients, and tissue fragments compatible with aortic valve leaflet or aortic wall origin were found in 52 % (21/40) of patients [43] . Post-implantation balloon dilation, valve dislodgement, and attempts to deploy a second valve were found to be independent risk factors of stroke. Although several cerebral protection devices such as Montage Dual Filter System (Claret Medical Inc, Santa Rosa, CA) and Emob-X (Edwards Lifesciences, Irvine, CA) have received CE mark approval, their use has largely been restricted to clinical trials due to differing preliminary results [44] 
Vascular Complications
Vascular complications are most frequently related to procedural access. Major complications include thoracic aortic dissection, distal embolization (non-cerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage, access site or access-related injury leading to death, the need for blood transfusion (>4 units), unplanned percutaneous or surgical intervention, or irreversible end-organ damage. Minor vascular complications include access site or access-related injury not requiring unplanned percutaneous or surgical intervention and not resulting in end-organ damage [31•] .
At 30 days, major vascular complications were identified in 11.0 % of the TAVI group compared to 3.2 % of the high-risk AVR group (p < 0.001) in PARTNER (high-risk cohort) [24] . The trend was similarly present, albeit with a lower incidence, in the CoreValve trial, with 5.9 % of TAVI patients experiencing major vascular complications vs 1.7 % of high-risk AVR patients [31•] ( Table 2 ). Utilization of smaller sheaths has decreased the rate of vascular injury. Vessel size, calcification, and tortuosity in access vessels are important determinants for vascular injury related to sheath insertion. Vessel diameter in relation to sheath size is considered the most predictive factor [45] .
In the VARC-2 update, rupture of the device landing zone (which includes the aortic annulus and root, and the left ventricular outflow tract) was included among the vascular complications, whereas percutaneous closure device failure (leading to treatment other than manual compression or adjunctive endovascular ballooning) was defined as a distinct component of vascular complications, separate from the minor and major categories [38] .
Device landing zone rupture is a rare (1 %) but highly lethal complication. It has been reported with both balloon-expandable and self-expanding valves. Reported risks in the literature vary considerably, especially prior to VARC publications. CoreValve historically had lower vascular complications, due to its smaller sheath. The similar sheath profile of the current Edwards and Medtronic platforms theoretically reduces the risk. With the recent addition of 14-16Fr sheaths and careful screening for access site, assessing vessel caliber, calcifications, angulation, and tortuosity, the rate of access complications has drastically decreased. A study of 375 consecutive patients with severe AS who underwent transfemoral TAVI found a lower incidence of major vascular complications and bleeding using a low-profile (14-18Fr) sheath as opposed to a high-profile (19-24Fr) sheath (0.5 vs 10.5 %, p < 0.001 and 3.4 vs 8.3 %, p = 0.038, respectively) [46] . Access site complications also decrease as TAVI group experience increases. 
Bleeding
Bleeding is defined as Blife-threatening^or Bdisabling^if it leads to death; occurs in a critical area, such as the central nervous system, the pericardium (requiring drainage), or in the muscle with compartment syndrome; causes shock or severe hypotension; leads to a drop of ≥5 g/dl in hemoglobin; or requires transfusion of ≥4 units of red blood cells. When hemorrhage does not meet these criteria, but is associated with a drop in hemoglobin ≥3 g/dl or requires transfusion of 2-3 units of red blood cells, the bleeding is classified as Bmajor.^Any other bleeding that does not fulfill these criteria, but is worth mentioning is considered to be Bminor^ [40] .
A total of 71 (22.7 %), 27 (11.3 %), and 9 (8.8 %) patients had major bleeding within 30 days of the procedure after AVR, transfemoral-TAVI, and transapical-TAVI, respectively (p < 0.0001) [47] . Access site complications can lead to a significant amount of bleeding. Hemorrhage has also been noted in the retroperitoneum and gastrointestinal tract. Bleeding is an independent risk factor of mortality with a hazard ratio of 2.5 [48] . Pericardial tamponade can be caused by right ventricular perforation by temporary pacemaker wires, aortic annulus rupture, aortic dissection, and left ventricular perforation owing to stiff wires placed in the left ventricular cavity. Therapeutic approaches include manual pressure, anticoagulation reversal, balloon occlusion of the contralateral side and possible covered stent deployment, and direct surgical exploration and repair.
Acute Kidney Injury
The etiology of acute kidney injury (AKI) following TAVI is multifactorial and frequently occurs in patients with diabetes mellitus, chronic kidney disease, and peripheral vascular disease [49] . While there was no difference in the rate of AKI in the PARTNER 1 trial (1.2 % in the TAVI group vs 1.2 % in the SAVR group, p = 0.95), AKI was more common in the SAVR group in the CoreValve trial (6.0 % vs 15.1 %, p < 0.001) [24, 31•] . Events such as debris emboli into the renal artery, hypotension during rapid pacing, and use of contrast are risk factors for developing AKI. To prevent AKI, prophylactic measures include optimal hydration, minimal contrast use, and cessation of nephrotoxic drugs as part of the standard care for TAVI patients.
Aortic Valve Regurgitation
Following valve deployment, it is imperative to assess for AR and distinguish between valvular and PVR using aortic root angiogram, echocardiogram, and clinical status (e.g., low diastolic blood pressure). While mild regurgitation can be an acceptable result, moderate or greater regurgitation is defined as a procedural failure and should be addressed during the procedure. Severe aortic valvular regurgitation may indicate a Bfrozen leaflet^ [50] , which can be corrected by manipulation of the frozen leaflet with a coronary catheter, or if necessary, the implantation of a second valve.
Three main mechanisms contribute to post-TAVI PVR. First, suboptimal prosthesis placement with incomplete sealing of the annulus by the skirt owing to positioning the prosthesis too high or too low. Second, incomplete stent frame apposition owing to calcification of the annulus, the native leaflets, or the left ventricular (LV) outflow tract (device landing zone). Third, mismatch between the size of the annulus and the size of the prosthesis owing to undersizing of the replacement aortic valve. Correct sizing of the annulus with mild oversizing should ensure the prosthesis is large enough to minimize PVR, without excessive oversizing, which could lead to annular injury [40] .
Paravalvular leak (PVL) can potentially be corrected by post-implantation dilation, at the expense of potential annular rupture, stroke, or device dislodgement. If the original device was malpositioned, implantation of a second valve should be considered. Percutaneous PVL closure has been reported [51] .
Valve Malpositioning
Malpositioning can occur either after appropriate deployment or the valve can be malpositioned primarily. Causes of malpositioning include undersized valves, inadequate visualization/parallax, inadequate rapid ventricular pacing for balloon-expandable valves, hypertrophic obstructive cardiomyopathy, mitral valve prosthesis, or severe calcification of the mitral annulus.
The rate of valve malpositioning ranges from 0.8 to 5.6 % (pooled rate 3.5 %, 95 % CI 2.2-5.6 %) [52] . Malpositioning of self-expandable valves is usually treated either by pulling the valve back towards the aorta with a snare for the CoreValve or implantation of a second valve-in-valve, which can also be performed when a balloon-expandable valve has migrated. Treatment of aortic embolization of a balloon-expandable valve should involve retrieval of the valve within the descending aorta using an inflated balloon placed within the prosthesis. Once retrieved to the descending aorta, the embolized balloon-expandable valve is then deployed with the balloon, and can then be secondarily stented to render it non-functional. In addition, avoiding withdrawal of the guidewire is imperative to prevent inversion of the valve prosthesis [40] . Conversely, management of ventricular embolization requires emergency surgical removal of the valve, although transapical extraction or balloon recapture and repositioning within the aortic valve or the aorta have been described [53] .
Coronary Obstruction
Coronary obstruction is defined as an angiographic or echocardiographic evidence of a new, partial, or complete obstruction of a coronary ostium during or after TAVI [38] . Coronary obstruction occurs in 0.8 % of primary procedures, but this rate increases to 3.5 % for valve-in-valve procedures [33, 54] . The left main coronary artery is the most frequently occluded. Usually, the coronary ostia become occluded by the coronary cusps of the native valve, especially if bulky calcific nodules are present on the valve leaflets. Narrow aortic root, shallow sinuses, and low (<10-12 mm) position of the coronary ostia are associated with an increased risk of this complication.
If the patient has a prohibitive risk for surgery and high-risk anatomical features for coronary obstruction, placement of 0.014 guidewires into coronary vessels will allow prompt percutaneous coronary intervention (PCI) if signs of ostial obstruction appear. Consequently, circulatory assistance should be available at every TAVI case.
Periprocedural Myocardial Infarction (MI)
VARC defines peri-procedural myocardial infarction (MI) as the presence of new ischemic signs (imaging evidence of new loss of viable myocardium or new wall motion abnormality, new ST segment changes, new pathological Q waves in at least two contiguous leads, hemodynamic instability, ventricular arrhythmias, or new or worsening heart failure) or symptoms (chest pain or shortness of breath), associated with an elevation in cardiac biomarkers (preferably creatine kinase MB) within 72 h of the procedure [38] .
The majority of patients undergoing TAVI sustain some degree of the myocardial injury (increased troponin levels) [40] but only about 1 % sustain peri-procedural MI defined by VARC [54] . Potential causes of peri-procedural MI include ischemia related to hypotension or rapid ventricular pacing, myocardial tissue compression by prosthesis expansion, coronary micro-embolism, and direct trauma of the ventricular apex during the transapical approach. Baseline renal dysfunction, the presence of peripheral artery disease, the absence of pre-procedural β-blocker use, the use of the transapical approach, procedural duration, and prosthesis implantation depth (for the CoreValve®) are all independent predictors of myocardial injury during TAVI [55] .
Arrhythmias
New onset AF after TAVI is lower than the incidence of AF in AVR and ranges up to 12-16 vs 17-34 % at 12 months. Risk factors for developing of AF include left atrial distension and using a transapical approach. AF was not a predictor of mortality [42] .
Heart block following TAVI includes first-degree AV block, second-degree AV block (Mobitz I or Mobitz II), third-degree AV block, bundle branch block, and AV block requiring pacemaker insertion. The new permanent pacemaker (PPM) rate in the PARTNER trial was similar between TAVI and AVR groups (5.75 vs 5.0 %). In the CoreValve trial, the rate of new PPM in the TAVI group was 22.3 % compared to 11.3 % in the AVR group at 1 year (p < 0.001) ( Table 2) . A recent meta-analysis revealed left anterior hemiblock, intraoperative atrioventricular (AV) block, right bundle branch block, and Medtronic CoreValve (compared to Edwards Sapien valve) were associated with an increased risk of permanent pacemaker placement following TAVI [56] .
Future Directions
Several ongoing studies are currently assessing TAVI efficacy in lower risk groups, for which there are presently no commercially available platforms. PARTNER 2 is a prospective trial of patients undergoing AVR for severe aortic stenosis which includes intermediate-risk patients defined as an STS-PROM >4 %, but <8 %. The SAPIEN XT was studied in intermediate-risk patients randomized to receive TAVI with the SAPIEN XT or AVR, and a 2-year follow-up is ongoing. Moreover, the Sapien 3 valve is currently being studied in intermediate-risk patients in a non-randomized assignment [57] . Medtronic is currently sponsoring a randomized openlabel study comparing AVR and TAVI (CoreValve and CoreValve Evolut R systems) in the intermediate-risk population in the SURTAVI trial which includes elderly (≥70 years) patients with AS and an STS score between 4 and 10 %. Approximately 2500 patients will be randomly assigned to TAVI with CoreValve or AVR in approximately 75 centers across Europe, Canada, and the USA. In addition, the Nordic Aortic Valve Intervention Trial (NOTION) is randomizing patients ≥70 years of age, irrespective of expected surgical risk, to either TAVI with CoreValve or AVR.
Innovations aimed at reducing the complication profile of the procedure continue to be developed. The Claret Montage TM Dual Filter System (Claret Medical, Inc., Santa Rosa, CA, USA), Shimon embolic filter TM (SMT Research and Development, Herzliya, Israel), and Embrella® embolic deflector system (Embrella Cardiovascular, Inc., Wayne, PA, USA) are devices designed to protect cerebral circulation during TAVI which may soon become available in the USA. Although no official guidelines have been published, anticoagulation strategies and periprocedural AF management can potentially decrease the risk of stroke and TIA. An ongoing phase IV clinical trial randomizes patients with severe AS to post-TAVI antithrombotic treatment with either antiplatelet therapy with aspirin and clopidogrel or oral anticoagulation with coumadin to assess the rate of cerebral thromboembolism [58] . TAVI patients with AF may be ideally suited to anticoagulation with novel oral anticoagulants. A trial comparing warfarin with factor Xa inhibitor apixaban in patients with AF found lower rates of stroke or systemic embolism (1.27 % per year vs 1.60 % per year, p < 0.001), bleeding (2.13 % per year vs 3.09 % per year, p < 0.001), and mortality (3.52 vs 3.94 %, p = 0.047) in patients randomized to apixaban compared to warfarin [59] .
Future studies should also address the management of concomitant coronary artery disease, arrhythmia management, and the long-term durability of TAVI devices, which is of particular importance for younger, low-risk patients.
Conclusions
TAVI has emerged as an effective therapeutic option for highrisk patients with severe symptomatic AS. In addition, TAVI has become a valuable option for valve-in-valve implantation to treat failed bioprosthetic valves. AVR remains the gold standard for low and intermediate risk patients. However, with evidence of clinical efficacy in lower risk patients, TAVI indications may expand in the near-future. Long-term data on TAVI durability and complications is needed. Multidisciplinary care remains a tenet essential to the optimal management of patients undergoing TAVI.
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